Global Cell-Free DNA Testing Market – Industry Analysis and Forecast (2019-2026)Posted by rahul on April 2nd, 2021 Global Cell-free DNA testing market was valued US$ 104.69 Mn in 2019 and is expected to reach US$ XX Mn by 2026, at a CAGR of XX % during a forecast period. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. To know about the Research Methodology:-Request Free Sample Report Cell-free DNA (cfDNA) is also called NIPT. The non-invasive prenatal test is a new technology being used to assess the risk of a pregnant woman's and taking a sample of blood from the vein rather than inserting a needle into the uterus similar to amniocentesis. The cell-free DNA testing is used in many fields such as gynecology, oncology, and transplantation to identify mutations in cancer patients and identify various chromosomal abnormalities in the fetus, to know the gender of the fetus. Increasing healthcare expenditure, and growing healthcare awareness are the key reasons driving the cell-free DNA market. The risk of chronic diseases owing to unhealthy lifestyle and food habits is expected to drive the growth of cell-free DNA testing market. Health damaging lifestyle actions such as the increased use of tobacco & alcohol, lack of physical activity, poor eating habits or heavy consumption of fast foods are the major factors for responsible for chronic diseases. Inherited abnormalities among infants are also increasing across the globe because of advanced maternal age. Advances in molecular pathogenesis, growing parasitic infection, the surge in prenatal complication, and alertness for prenatal testing offer potential growth opportunities for market expansion. However, problems like high test cost, lack of skilled healthcare professional and ethical issues related to genetic testing are obstructing the growth of the cfDNA testing market. Growing alertness in the people and requirement of safe & low-risk obstetric procedures for prenatal testing. The growth of cell-free fetal DNA testing market is mainly expected to exact and effective results for aneuploidy screening. NIPT is a screening test which offers information regarding only Down syndrome trisomy 21, trisomy 18 and trisomy 13. A trisomy occurs when there is an extra copy of a particular chromosome in every single cell. Down syndrome is generally caused by an error in cell division called “nondisjunction.” It caused when abnormal cell division results in extra genetic material from chromosome 21. North America is expected to hold the largest market share during the forecast period followed by Europe and Asia-Pacific. Owing to the rising mandate for a non-invasive test for cancer screening and clinical & research studies. An increasing prevalence of diseases related to lifestyle change and government initiatives in establishing innovative technologies and demand for sophisticated medical services is estimated to grow in significant rate in the Asia-Pacific region. Key player operating in the global cell-free DNA testing market are Berry Genomics Co. Ltd, Bgi, Biocartis, Biocept, Inc., Biodesix, Inc., Boreal Genomics, Caredx, Inc., Chronix Biomedical, Circulogene Theranostics, Counsyl, Inc., Cynvenio Biosystems Inc, Exact Sciences, Foundation Medicine, Gatc Biotech, Guardant Health, Inc, Illumina, Inc., Inivata Limited, Laboratory Corp. Of America Holdings, Lifecodexx Ag, Molecular Md, Multiplicom Nv, Natera, Inc., Neo New Oncology Ag, Neogenomics Laboratories, Pathway Genomics, Personal Genome Diagnostics, Predicine Holdings Ltd., Premaitha Health Plc, Prenatalis, Quest Diagnostics, Roche Holdings Ag, Sequenom, Inc., Sysmex Inostics, Tai Diagnostics, Inc., The Chinese University Of Hong Kong, Transgenomic, Inc., and Trovagene, Inc. The objective of the report is to present comprehensive analysis of Global Cell-free DNA testing Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Cell-free DNA testing Market dynamics, structure by analyzing the market segments, and project the Global Cell-free DNA testing Market size. Clear representation of competitive analysis of key players by Global Cell-free DNA testing Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Cell-free DNA testing Market make the report investor’s guide. visit at-https://www.maximizemarketresearch.com/market-report/global-cell-free-dna-testing-market/22142/
Global Cell-Free DNA Testing Market, by Products: • Donor-Derived Cell-Free DNA (DdcfDNA) • NGS • Oncology • North America • Berry Genomics Co. Ltd About Us: Maximize Market Research provides B2B and B2C market research on Like it? Share it! More by this author |